How Novo Nordisk lobbied AHPRA and the TGA to get compounded semaglutide banned
The Danish multinational company appealed directly to AHPRA, the TGA and Mark Butler for an intervention.
More than a year before the Federal Government announced its compounding ban, the pharmaceutical giant Novo Nordisk was making complaints to AHPRA about pharmacies compounding its semaglutide blockbuster drug.
The multibillion-dollar company — recently named the 12th biggest in the world — claimed that pharmacists were putting patients at serious risk and urged both AHPRA and the Pharmacy Board of Australia to write to all registered pharmacists and demand “the immediate cessation of this practice”.
